S.Res. 510 · 118th Congress · Senate

A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

Active· Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S6003-6004)
Introduced
Dec 14, 23
Passed Senate
Pending
Passed House
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

This resolution expresses the sense of the Senate that (1) policies governing access to medication abortion care should be based on scientific review by the Food and Drug Administration (FDA), and (2) the FDA has found mifepristone to be safe and effective for women seeking abortions.

Action Timeline

2
  1. DEC 14, 2023•IntroReferral

    Introduced in Senate

  2. DEC 14, 2023•IntroReferral

    Referred to the Committee on Health, Education, Labor, and Pensions

    (text: CR S6003-6004)

    6003Yea
    6004Nay
    0NV

Committees

1

Health, Education, Labor, and Pensions Committee

sshr00

Referred: Dec 14, 2023

Active